Background: Adjuvant treatment concepts have improved the 10-year cure rate of breast and colon cancer, but new treatments for metastatic disease have yielded only incremental benefit. If treatments for disseminated cancer were actually prolonging life rather than only increasing remission rates, this effect should have been documented over the last 30+ years. However, published data concerning advances in treatment for disseminated cancer have been contradictory. Patients and Methods: To add data-based information, we analyzed 2 sources: a regional population-based cancer registry (Hamburgisches Krebsregister, HKR), and a research cancer registry (Projektgruppe Internistische Onkologie, PIO). We compared the survival of several thousand patients with metastatic disease who received treatment only after dissemination with that of patients who received initial adjuvant therapy. Results: After adjuvant treatment, survival in patients with disseminated breast cancer is up to a third shorter than that of patients without adjuvant therapy. Conclusions: In accordance with published evidence, we conclude that ineffective adjuvant treatment shortens survival after documentation of metastatic disease. This is probably due to the elimination of chemo-sensitive tumor cells or to the induction of resistance in remaining micrometatases. This negative effect on survival after dissemination has been shown clearly for breast cancer and is also probable for cancer of the colon and other sites.

1.
Giordano SH, Buzdar AU, Smith TL, et al.: Is breast cancer survival improving? Cancer 2004; 100:44-52.
2.
Dafni U, Grimani I, Xyrafas A, et al.: Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010;119:621-631.
3.
Saad ED, Buyse M: Overall survival: Patient outcome, therapeutic objective, clinical trial end point, or public health measure? J Clin Oncol 2012; 30:1750-1754.
4.
Shanafelt TD, Loprinzi C, Marks R, et al.: Are chemotherapy response rates related to treatment induced survival prolongations in patients with advanced cancer? J Clin Oncol 2004;22:1966-1974.
5.
Niraula S, Seruga B, Ocana A, et al.: The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 2012; 30:3012-3019.
6.
Kleeberg UR: Weitere Erfolge der medizinischen Onkologie oder eher der Wunsch als Vater des Gedankens? InFo Onkologie 2011;14:3-5.
7.
Hakulinen T, Seppä K, Lambert PC: Choosing the relative survival method for cancer survival estimation. Eur J Cancer 2011;47:2202-2210.
8.
Berkson J, Gage RP: Calculation of survival rates for cancer. Proc Staff Meet Mayo Clin 1950;25:270-286.
9.
Cutler SJ, Ederer F: Maximum utilisation of the life table method in analyzing survival. J Chron Dis 1958; 8:699-712.
10.
Ederer F, Axtell LM, Cutler SJ: The relative survival rate: A statistical methodology. Natl Cancer Inst Monogr 1961;6:101-121.
11.
Hakulinen T: Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 1982;38: 933-942.
12.
Manton KG, Stallard E, Woodbury MA, et al.: Time varying covariates in models of human mortality and aging: Multidimensional generalizations of the Gompertz. J Gerontol A Biol Sci Med Sci 1994;49:B169-B190.
13.
Federal Statistical Office. Period life tables for Germany 1871/1881 to 2008/2010. https://www.destatis.de/DE/Publikationen/Thematisch/Bevoelkerung/Bevoelkerungsbewegung/Periodensterbetafeln.html PDF_5126202.pdf?__blob=publicationFile
14.
Holleczek B, Gondos A, Brenner H: PeriodR - an R package to calculate long-term cancer survival estimates using period analysis. Methods Inf Med 2009;48:123-128.
15.
Estève J, Benhamou E, Raymond L: Statistical methods in cancer research. Descriptive epidemiology, vol. IV. IARC Sci. Publ. 1994;128:1-302.
16.
Brenner H, Hakulinen T: Are patients diagnosed with breast cancer before age 50 years ever cured? J Clin Oncol 2004;22:432-438.
17.
André F, Slimane K, Bachelot T, et al.: Breast cancer with synchronous metastases: Trends in survival during a 14-year period. J Clin Oncol 2004;22:3302-3308.
18.
Schlesinger-Raab A, Eckel R, Engel J, et al.: Metastasiertes Mammakarzinom: Keine Lebensverlängerung seit 20 Jahren. Dtsch Ärztebl 2005; 102: A2706-2709.
19.
Van den Hurk CJG, Eckel R, van de Poll-Franse LV, et al.: Unfavorable pattern of metastases in M0 breast cancer patients during 1978-2008: A population-based analysis of the Munich Cancer Registry. Breast Cancer Res Treat 2011;128:795-805.
20.
Dawood S, Broglio K, Conzales-Angelo AM, et al.: Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 2009; 26:4891-4898.
21.
Cortès J, Calvo E, González-Martin A, et al.: Progress against solid tumors in danger: The metastatic breast cancer example. J Clin Oncol 2012;30:3444-3447.
22.
Pierga J-Y, Asselain B, Jouve M, et al.: Effect of adjuvant chemotherapy on outcome in patients with metastatic breast cancer treated with first-line doxorubicin-containing chemotherapy. Cancer 2001;91:1079-1089.
23.
Hölzel D, Engel J: Klinische Krebsregister: Auf Erfahrungen aus dem Alltag kann nicht verzichtet werden. Dtsch Ärztebl 2012;109:A424-425.
24.
Chlebowski RT, Weiner JM, Luce J, et al.: Significance of relapse after adjuvant treatment with combination chemotherapy or 5-FU alone for high risk breast cancer. Cancer Res 1981;41:4399-4403.
25.
Ahmann FR, Jones SE, Moon TE: The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer. J Surg Oncol 1988;37:116-122.
26.
Yamamoto N, Watanabe T, Katsumata N, et al.: Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 1998;16:2401-2408.
27.
Lluch A, Ojeda B, Colomer R, et al.: Doxorubicin and paclitaxel in advanced breast carcinoma. Cancer 2000;89:2169-2175.
28.
Alba E, Ribelles N, Sevilla I, et al.: Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer. Breast Cancer Res Treat 2001; 66:33-39.
29.
Miller K, Wang N, Gralow J, et al.: Paclitaxel plus Bevacizumab versus Paclitaxel alone in metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
30.
Vauléon E, Mesbah H, Laguerre B, et al.: Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challenge. Cancer Chemother Pharmacol 2010;66:113-120.
31.
Mittendorf EA, Wu Y, Scaltriti M, et al.: Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic chemotherapy and survival outcomes. Clin Cancer Res 2009;15:7381-7388.
32.
Murthy RK, Varma A, Mishra P, et al.: Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting. ASCO Annual Meeting 2012; abstract no. 527.
33.
Lindström LS, Karlsson E, Wilking UM, et al.: Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012;30:2601-2608.
34.
Gerlinger M, Rowan AJ, Horswell S, et al.: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-892.
35.
Bai H, Wang Z, Cen K, et al.: Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 2012;30:3077-3083.
36.
Moertel CG, Fleming TR, Macdonald JC, et al.: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 1995; 122:321-326.
37.
O'Connell MJ, Campbell ME, Goldberg RM, et al.: Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol 2008;26:2336-2341.
38.
A'Hern RP, Ebbs SR, Baum MB: Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer 1988;57: 615-618.
39.
Gennari A, Stockler M, Puntoni M, et al.: Duration of chemotherapy for metastatic breast cancer: A systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011;29:2144-2149.
40.
Cardoso F, Di Leo A, Lohrisch C, et al.: Second and subsequent lines of chemotherapy for metastatic breast cancer: What did we learn in the last two decades? Ann Oncol 2002;13:197-207.
41.
Seruga B, Herz PC, Wang L, et al.: Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. Ann Oncol 2010; 21:1411-1418.
42.
Fink M: Nur kleine Schritte zur selektiven Chemotherapie: Adjuvante Therapie kann auch schaden. InFo Onkologie 2006;9:401-402.
43.
Lönn U, Lönn S, Nilsson B, et al.: Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy. Cancer 1996;77:107-112.
44.
Sun Y, Campisi J, Higano C, et al.: Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT168. Nat Med 2012;18:1359-1368.
45.
Creigthon CJ, Xiaoxian L, Landis M, et al.: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009;106:13820-13825.
46.
Long III HJ: Management of metastatic cervical cancer: review of the literature. J Clin Oncol 2007;25:2966-2974.
47.
Booth CM, Eisenhauer EA: Progression-free survival: Meaningful or simply measurable? J Clin Oncol 2012;30:1030-1033.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.